Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The biotech industry saw a surge in IPOs at the beginning of 2024, with industry insiders discussing the potential for continued growth. Bayer has postponed its plans to split up its divisions, causing a drop in company shares. Apogee, a biotech company, revealed promising early results for a potential long-lasting eczema drug. Nocion secured $62 million for its chronic cough drug, aiming to compete with a drug acquired by GSK. CVS and Walgreens will start selling the abortion pill in some states ahead of a Supreme Court case. The biosimilars market in the US has seen more products entering the market after a slow start. Additionally, topics such as gene therapy, FDA approvals, drug pricing, and clinical trials are covered in-depth by Biopharma Dive.Transitioning to the next news segment, Novo Nordisk's Ozempic has shown significant benefits in patients with type 2 diabetes and chronic kidney disease, leading to potential cardiometabolic expansion. Biopharma venture capital funding dropped by 20% in Q4 2023, with companies inking 204 deals totaling $6.3 billion. Other developments include Hugel challenging Botox with FDA approval for a neurotoxin injection for frown lines, Eyenovia and Formosa gaining FDA approval for an anti-inflammatory eye drop, and Vivoryon's stock plummeting after an Alzheimer's candidate failed a mid-stage trial. Pfizer has decided to focus on biologics over small molecules, and a pilot study showed better econsents lead to better human experiences. Bio 2024 is set to be the world's largest biotech event, offering opportunities for collaboration and innovation.Moving on to the next news piece, Dr. Marcus Conant, a doctor who treated some of the first patients with HIV in San Francisco in the 1980s, is now working towards finding a cure for the virus. Despite the lack of action and lessons learned from previous epidemics like AIDS, researchers are getting closer to potentially eradicating HIV. The medical and political landscapes have changed, but the fight against HIV continues. Conant's story sheds light on the progress made in the research for a cure, highlighting the urgency of finding more effective treatments as time passes. The biotech sector has seen an increase in IPOs in 2024, sparking optimism in the industry.Lastly, Abingworth has invested in the development of Trodelvy in a deal with Gilead, while Ginkgo acquired a gene editing startup founded by Feng Zhang. FogPharma received $145 million to support cancer drug research, and Nocion secured $62 million for a chronic cough drug. Cure Ventures backed a cell therapy startup targeting Parkinson's, and former Turning Point executives launched a new startup targeting cancer and autoimmune diseases. The biotech IPO market is heating up in 2024, with emerging trends being closely watched. These developments highlight the dynamic and competitive nature of the biopharma industry, with companies racing to bring innovative treatments to market.